CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Dapsone

氨苯砜 杂质对照品Dapsone Impurities

24 个杂质条目24 impurity entries

本页汇总 氨苯砜 的 24 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 24 impurity reference standards of Dapsone. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 氨苯砜(Dapsone)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesImpurity profiling of dapsone using gradient HPLC method
    Journal of pharmaceutical and biomedical analysis · 2021 · Leistner A, Holzgrabe U  ·  PMID 33657522  ·  DOI
  2. 杂质研究Impurity studiesFormation and identification of a degradant in chlorproguanil-dapsone-artesunate (Dacart™) tablets
    Journal of pharmaceutical and biomedical analysis · 2011 · Bardsley B et al.  ·  PMID 20970278  ·  DOI
  3. 杂质研究Impurity studiesFormulation development and stabililty testing of extemporaneous suspension prepared from dapsone tablets
    International journal of pharmaceutical compounding · 2003 · Kaila N et al.  ·  PMID 23979648
  4. 分析方法Analytical MethodsChromatographic method for the simultaneous quantification of dapsone and clofazimine in nanoformulations
    Journal of separation science · 2018 · Machado S et al.  ·  PMID 30006947  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisA century of the synthesis of dapsone: its anti-infective capacity now and then
    International journal of dermatology · 2000 · Wolf R, Orni-Wasserlauf R  ·  PMID 11095201  ·  DOI

氨苯砜 —— 原料药与杂质对照品Dapsone — drug substance & impurities

共 25 个条目(含原料药本体)25 items incl. the drug substance
Dapsone structure
原料药 APIAPI
氨苯砜Dapsone
Dapsone
CAS No.80-08-0
Chemical FormulaC12H12N2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Monoacetyl Dapsone-d8 structure
—
一乙酰氨苯砜-d8Monoacetyl Dapsone-d8
Monoacetyl Dapsone-d8
CAS No.1215635-13-4
Chemical FormulaC14H6D8N2O3S
Purity>95%询价On request
Dapsone Impurity 1(Dapsone hydroxylamine) structure
1
氨苯砜杂质1(氨苯砜羟胺盐)Dapsone Impurity 1(Dapsone hydroxylamine)
Dapsone Impurity 1(Dapsone hydroxylamine)
CAS No.32695-27-5
Chemical FormulaC12H12N2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 2(Monoacetyl Dapsone) structure
2
氨苯砜杂质2(一乙酰氨苯砜)Dapsone Impurity 2(Monoacetyl Dapsone)
Dapsone Impurity 2(Monoacetyl Dapsone)
CAS No.565-20-8
Chemical FormulaC14H14N2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 3 structure
3
氨苯砜杂质3Dapsone Impurity 3
Dapsone Impurity 3
CAS No.2514651-21-7
Chemical FormulaC24H22N4O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 4 structure
4
氨苯砜杂质4Dapsone Impurity 4
Dapsone Impurity 4
CAS No.80-00-2
Chemical FormulaC12H9ClO2S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 5 structure
5
氨苯砜杂质5Dapsone Impurity 5
Dapsone Impurity 5
CAS No.7146-68-1
Chemical FormulaC12H10ClNO2S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 6 structure
6
氨苯砜杂质6Dapsone Impurity 6
Dapsone Impurity 6
CAS No.25963-47-7
Chemical FormulaC12H11NO3S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 7 structure
7
氨苯砜杂质7Dapsone Impurity 7
Dapsone Impurity 7
CAS No.7019-01-4
Chemical FormulaC12H11NO2S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 8 structure
8
氨苯砜杂质8Dapsone Impurity 8
Dapsone Impurity 8
CAS No.27147-69-9
Chemical FormulaC12H12N2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 9 structure
9
氨苯砜杂质9Dapsone Impurity 9
Dapsone Impurity 9
CAS No.54616-64-7
Chemical FormulaC24H20N2O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 10 structure
10
氨苯砜杂质10Dapsone Impurity 10
Dapsone Impurity 10
CAS No.22100-66-9
Chemical FormulaC12H8N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 11 structure
11
氨苯砜杂质11Dapsone Impurity 11
Dapsone Impurity 11
CAS No.14665-52-2
Chemical FormulaC12H8N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 12 structure
12
氨苯砜杂质12Dapsone Impurity 12
Dapsone Impurity 12
CAS No.53347-49-2
Chemical FormulaC12H12N2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 13 structure
13
氨苯砜杂质13Dapsone Impurity 13
Dapsone Impurity 13
CAS No.116435-84-8
Chemical FormulaC12H12N2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 14 structure
14
氨苯砜杂质14Dapsone Impurity 14
Dapsone Impurity 14
CAS No.106917-52-6
Chemical FormulaC13H7Cl2F3N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 15 structure
15
氨苯砜杂质15Dapsone Impurity 15
Dapsone Impurity 15
CAS No.119-59-5
Chemical FormulaC12H12N2OS
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 16 structure
16
氨苯砜杂质16Dapsone Impurity 16
Dapsone Impurity 16
CAS No.101-59-7
Chemical FormulaC12H10N2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 17 structure
17
氨苯砜杂质17Dapsone Impurity 17
Dapsone Impurity 17
CAS No.80-07-9
Chemical FormulaC12H8Cl2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 18 structure
18
氨苯砜杂质18Dapsone Impurity 18
Dapsone Impurity 18
CAS No.53566-73-7
Chemical FormulaC12H8N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 19 structure
19
氨苯砜杂质19Dapsone Impurity 19
Dapsone Impurity 19
CAS No.21387-93-9
Chemical FormulaC12H8N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 20 structure
20
氨苯砜杂质20Dapsone Impurity 20
Dapsone Impurity 20
CAS No.154043-92-2
Chemical FormulaC36H24O9S3
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 21 structure
21
氨苯砜杂质21Dapsone Impurity 21
Dapsone Impurity 21
CAS No.872811-58-0
Chemical FormulaC12H11NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 22 structure
22
氨苯砜杂质22Dapsone Impurity 22
Dapsone Impurity 22
CAS No.2755500-71-9
Chemical FormulaC24H20N4O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Dapsone Impurity 23 structure
23
氨苯砜杂质23Dapsone Impurity 23
Dapsone Impurity 23
CAS No.64896-96-4
Chemical FormulaC12H10ClNO2S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

氨苯砜 —— 研究文献与合成路线Dapsone — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 氨苯砜 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Dapsone. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Formation and identification of a degradant in chlorproguanil-dapsone-artesunate (Dacart™) tablets
    Bardsley B, Barry SJ, Drozdz MA, et al. · Journal of pharmaceutical and biomedical analysis · 2011 · 被引 5cited 5
  2. Impurity profiling of dapsone using gradient HPLC method
    Leistner A, Holzgrabe U · Journal of pharmaceutical and biomedical analysis · 2021 · 被引 1cited 1
  3. Identification and quantitation of impurities in dapsone preparations
    Gordon GR, Ghoul DC, Peters JH · Journal of pharmaceutical sciences · 1975 · 被引 6cited 6
  4. Spectrophotometric determination of dapsone in pharmaceutical products using sodium 1,2-naphthoquinone-4-sulfonic as the chromogenic reagent
    Wang HY, Xu LX, Xiao Y, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2004 · 被引 9cited 9
  5. Determination of Arylamine N-Acetyltransferase 2 Acetylation Genotype by PCR and Phenotyping Using Dapsone Through High-Pressure Liquid Chromatography Assay: A Gender Wise Study
    Akhter N, Iqbal T, Jamil A, et al. · Dose-response : a publication of International Hormesis Society · 2019 · 被引 2cited 2
  6. Individual and simultaneous spectrophotometric determination of dapsone and metoclopramide HCl in pharmaceutical dosage forms and synthetic binary mixtures
    Omran AA · Chemical & pharmaceutical bulletin · 2005 · 被引 5cited 5

合成与制备工艺专利Synthesis & process patents

  1. USE OF DAPSONE AS A NEUROPROTECTOR IN PREPARING MEDICAMENT FOR BRAIN STROKE
    RIOS CASTANEDA LUIS CAMILO, ALTAGRACIA MARTINEZ MARINA, NADER KAWACHI JUAN, KRAVZOV JINICH JAIME · 公开号 HK1098086HK1098086 · 2009
  2. Galenical preparations of dapsone and related sulphones, and method of therapeutic and preventative treatment of disease
    ABERG A K GUNNAR, ZOLOTOY ALEXANDER, BAIN ALLEN I · 公开号 US2003092635US2003092635 · 2003
  3. GALENICAL PREPARATIONS OF DAPSONE AND RELATED SULPHONES, AND METHOD OF THERAPEUTIC AND PREVENTATIVE TREATMENT OF DISEASE
    ABERG A. K. Gunnar, BAIN Allen I., ZOLOTOY Alexander · 公开号 EP1237557EP1237557 · 2002
  4. GALENICAL PREPARATIONS OF DAPSONE AND RELATED SULPHONES, AND METHOD OF THERAPEUTIC AND PREVENTATIVE TREATMENT OF DISEASE
    ABERG A. K. Gunnar, ZOLOTOY Alexander, BAIN Allen I · 公开号 WO0141772WO0141772 · 2001

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

氨苯砜 杂质谱研究要点Dapsone — impurity profiling notes

下面这些是拿到 氨苯砜 的 25 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 25 impurity entries for Dapsone, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances